Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The EU notified body industry association, TEAM-NB, and the European Confederation of Notified Bodies Group (NB-Med), have drafted a position paper in a bid to clarify how to apply the EU MDR's regulatory provisions on spinal implants. The document features a risk-based decision tree to demonstrate whether spinal implants – both fusion and non-fusion devices – should be in risk class IIb or III. This will determine the amount of work that needs to be done.
Their joint work was prompted by the complex wording used in Classification Rule 8 of the MDR (contained in Annex VIII, 5.4), on implantable devices and long-term surgically-invasive devices. The two groups felt that this impeded a harmonized interpretation of the regulation, and moreover that it lacked clarity regarding the level of scrutiny that notified bodies would need to apply when overseeing the manufacturers of such devices.
This states that all implantable devices and long-term surgically-invasive devices are in class IIb unless they:
are total or partial joint replacements, in which case they are in class III, with the exception of ancillary components, such as screws, wedges, plates and instruments; or
are spinal disc replacement implants and implantable devices that come into contact with the spinal column, in which case they are in class III, with the exception of components such as screws, wedges, plates and instruments.
There are many complexities around this, however, as are listed in the Position Paper.
The two organizations say that “with this position paper, notified bodies are providing their view and interpretation to the various EU regulators, including the European Commmision, enabling them to comment and correct if deemed necessary.”
The authors of the position paper believe that the decision tree will reduce the number of unnecessary submissions for clinical evaluation consultation, a regulatory process involving a close scrutiny reserved for the highest-risk devices.
This, they say, is in line with the intended focus of the planned expert panels – on novel devices and devices with possible major clinical or health impacts.
“With this measure,” the authors add, "a smaller number of experts at the panel are needed, reducing the burden on the EU Commission to establish such an expert panel within a short period of time.”
They offer the following decision-tree on spinal implant classification:
|
Risk class |
|
Type of technology |
Degree of review |
|
IIb |
Fusion devices |
|
|
|
a) |
Well-established technologies
|
To be sampled according to typical rules for class IIb devices (at least one representative technical documentation per generic device group) |
|
|
b) |
Not so well-established technologies: |
Full review of technical documentation, similar to class III devices (100% sampling) |
|
|
|||
|
|||
|
|||
|
III |
Non-fusion devices(eg dynamic fixation) |
Subject to a clinical evaluation consultation procedure, including review by an expert panel as part of the scrutiny procedure |
|
Medtech Insight: global medical technology news & analysis
30 Sep 2020
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone...
Medtech Insight: global medical technology news & analysis
By Amanda Maxwell 30 Sep 2020
European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has...
Medtech Insight: global medical technology news & analysis
By Ferdous Al-Faruque 29 Sep 2020
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
